Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Harvard Business School
AstraZeneca
Boehringer Ingelheim
Baxter
Colorcon
Merck

Last Updated: November 22, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR SERLOPITANT

See Plans and Pricing

« Back to Dashboard

Clinical Trials for Serlopitant

Trial ID Title Status Sponsor Phase Summary
NCT01951274 VPD-737 for Treatment of Chronic Pruritus Completed Menlo Therapeutics Inc. Phase 2 A study of a several doses of a novel treatment for chronic itch compared to placebo for patients whose condition has not responded to other treatments
NCT02196324 A Randomized Placebo-Controlled Study of the Neurokinin-1 (NK1) Receptor Antagonist Serlopitant Prurigo Nodularis (PN) Completed Menlo Therapeutics Inc. Phase 2 The purpose of this study is to demonstrate whether or not VPD-737, an NK1 receptor antagonist is safe and effective for treatment of prurigo nodularis versus placebo.
NCT02654483 Neurokinin-1 Receptor Antagonist for the Treatment of Itch in EB Patients Recruiting Epidermolysis Bullosa Research Partnership Phase 2 Itch, or pruritus, is the most common complain reported by patients with epidermolysis bullosa (EB) of all subtypes, and there is no current effective treatment. Itch often triggers scratching that creates new wounds and increases EB disease severity. This study aims to target the physiological mechanisms of pruritus. Substance P is a major mediator of pruritus and binds to the receptor neurokinin-1 (NK1), which is expressed in the central nervous system and the skin. VPD-737 (serlopitant), a drug that inhibits the NK1 receptor, has been shown to reduce severe itch in a previous study of 257 adult patients with chronic pruritus. The investigators are now testing VPD-737 in 14 patients with EB in a Phase II randomized, placebo-controlled, double-blinded clinical trial. Our goals is to determine whether daily oral administration of VPD-737 (5 mg) is effective and safe in adolescents and adults with EB.
NCT02654483 Neurokinin-1 Receptor Antagonist for the Treatment of Itch in EB Patients Recruiting Menlo Therapeutics Inc. Phase 2 Itch, or pruritus, is the most common complain reported by patients with epidermolysis bullosa (EB) of all subtypes, and there is no current effective treatment. Itch often triggers scratching that creates new wounds and increases EB disease severity. This study aims to target the physiological mechanisms of pruritus. Substance P is a major mediator of pruritus and binds to the receptor neurokinin-1 (NK1), which is expressed in the central nervous system and the skin. VPD-737 (serlopitant), a drug that inhibits the NK1 receptor, has been shown to reduce severe itch in a previous study of 257 adult patients with chronic pruritus. The investigators are now testing VPD-737 in 14 patients with EB in a Phase II randomized, placebo-controlled, double-blinded clinical trial. Our goals is to determine whether daily oral administration of VPD-737 (5 mg) is effective and safe in adolescents and adults with EB.
NCT02654483 Neurokinin-1 Receptor Antagonist for the Treatment of Itch in EB Patients Recruiting Jean Yuh Tang Phase 2 Itch, or pruritus, is the most common complain reported by patients with epidermolysis bullosa (EB) of all subtypes, and there is no current effective treatment. Itch often triggers scratching that creates new wounds and increases EB disease severity. This study aims to target the physiological mechanisms of pruritus. Substance P is a major mediator of pruritus and binds to the receptor neurokinin-1 (NK1), which is expressed in the central nervous system and the skin. VPD-737 (serlopitant), a drug that inhibits the NK1 receptor, has been shown to reduce severe itch in a previous study of 257 adult patients with chronic pruritus. The investigators are now testing VPD-737 in 14 patients with EB in a Phase II randomized, placebo-controlled, double-blinded clinical trial. Our goals is to determine whether daily oral administration of VPD-737 (5 mg) is effective and safe in adolescents and adults with EB.
NCT02975206 Study of the Efficacy, Safety, and Tolerability of Serlopitant for Pruritus (Itch) in Atopic Dermatitis Recruiting Menlo Therapeutics Inc. Phase 2 Study of the Efficacy, Safety, and Tolerability of Serlopitant for Pruritus (Itch) in Atopic Dermatitis
>Trial ID >Title >Status >Phase >Summary

Clinical Trial Conditions for Serlopitant

Condition Name

Condition Name for
Intervention Trials
Pruritus 8
Prurigo Nodularis 4
Atopic Dermatitis 2
Psoriasis 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for
Intervention Trials
Pruritus 10
Prurigo 4
Neurodermatitis 3
Eczema 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Serlopitant

Trials by Country

Trials by Country for
Location Trials
United States 88
Germany 3
Poland 1
Austria 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for
Location Trials
California 6
Florida 5
Texas 5
North Carolina 5
New York 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Serlopitant

Clinical Trial Phase

Clinical Trial Phase for
Clinical Trial Phase Trials
Phase 3 3
Phase 2 9
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for
Clinical Trial Phase Trials
Recruiting 8
Completed 2
Not yet recruiting 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Serlopitant

Sponsor Name

Sponsor Name for
Sponsor Trials
Menlo Therapeutics Inc. 11
Epidermolysis Bullosa Research Partnership 2
Stanford University 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for
Sponsor Trials
Industry 11
Other 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Mallinckrodt
Moodys
Express Scripts
Boehringer Ingelheim
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.